Menopause and perimenopause: hormone therapy, what the trials show, and where GLP-1s fit

Reviewed 20 sourcesPublished by PepVault

Perimenopause and menopause explained: the stages, symptoms in numbers, what the hormone therapy trials found, the 2026 label change and non-hormonal options.

Blonde-grey woman in white linen walks barefoot on a beach, seen from an open deck with a table
Last reviewed
Sources
20
Questions
10
Compounds
2

The short answer

Perimenopause starts when your cycle length keeps shifting by 7 days or more and ends 12 months after your last period, at a median age near 52. Hormone therapy is the most effective hot-flash treatment, cutting flashes about 75% against placebo. Started before 60 or within 10 years of menopause, its benefits outweigh its risks for most women with bothersome symptoms. Bring those symptoms to a prescriber.

Every number checked at its primary source · · 20 sources · How we research

Evidence: Randomised trials (the two Women's Health Initiative trials, the SKYLIGHT and OASIS phase 3 trials), a Cochrane meta-analysis of 24 placebo-controlled trials, the SWAN cohort, the STRAW+10 staging consensus, the Menopause Society's 2022 position statement and current FDA labels; the GLP-1 result is a post hoc analysis of phase 3 trials.

Blonde-grey woman in white linen walks barefoot on a beach, seen from an open deck with a table

What are perimenopause and menopause?

Menopause is one day: your final menstrual period, confirmed only after 12 months without another. Perimenopause is the stretch around it, from the first lasting change in your cycle to that 12-month mark1. The stages come from STRAW+10, a 2011 consensus built on cohort studies of midlife women1. In SWAN, the US study that followed more than 3,000 women through the change, the median age at natural menopause was 51.4 in its screening survey and 52.5 in the women followed year by year [2, 3].

Two hormones move through it. FSH (follicle-stimulating hormone) is the brain's signal telling the ovaries to ripen an egg; it climbs as the ovaries answer less. Estradiol is the main estrogen the ovaries make; it falls. Both change fastest from about 2 years before the final period to 2 years after, then settle [1, 2].

STRAW+10 stageWhat marks itHow long it lasts
Early transition (−2)Cycle length differs by 7 days or more, again within 10 cycles; FSH raised but variable1Varies
Late transition (−1)60 days or more without a period; FSH sometimes above 25 IU/L11 to 3 years on average1
Early postmenopause (+1a to +1c)Starts at the final period; its first 12 months (+1a) confirm it. FSH keeps rising and estradiol falling for about 2 years15 to 8 years1
Late postmenopause (+2)Hormone changes slow; vaginal dryness becomes more common1The rest of life
A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault's bloodwork log keeps FSH and estradiol E2 panel by panel; type in the reference range printed on your lab report, since the app's default ranges are not menopause ranges.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Can a blood test tell if you are in perimenopause?

Not on its own. In the late transition FSH is sometimes in the menopausal range and sometimes back where it was in the reproductive years, especially when estradiol happens to be high that week1. SWAN found no single pattern of estradiol decline either: in about a third of women it rose some 5.5 years before the final period, then fell steeply in the last year2. STRAW+10 therefore stages women mainly by their bleeding pattern, with hormones as support1. Your cycle dates and symptoms carry more information than one draw.

  • Write down the start date of each period: a cycle that keeps running 7 or more days longer or shorter than the one before is the first sign.
  • Count your hot flashes and night sweats per day for a week; that per-24-hour count is what the drug trials measured.

PepVault's bloodwork log keeps FSH and estradiol E2 panel by panel; type in the reference range printed on your lab report, since the app's default ranges are not menopause ranges. Log it in PepVault

PepVault's weight log keeps your weight by date, typed in or synced from Apple Health, with body fat when you log it. Track your weight in PepVault

Which symptoms are most common, and how long do they last?

Hot flashes and night sweats lead. Up to 80% of SWAN women reported them at some point in the transition, most often as they moved from early to late perimenopause2. They last longer than most people expect: frequent hot flashes ran a median of 7.4 years in total and 4.5 years past the final period3. Women whose flashes began before or early in perimenopause had them longest, a median of more than 11.8 years, and Black women reported a median of 10.1 years3.

Trouble falling and staying asleep rose through the transition, and more frequent hot flashes went with more broken nights4. About 60% of midlife women report memory problems. SWAN's repeated testing found a small dip in perimenopause that cleared afterwards, and tied the slow long-term decline to age rather than to menopause2.

Commonly reported: hot flashes or night sweats, difficulty sleeping, stiffness or soreness, a pounding heart, forgetfulness, vaginal dryness and urine leakage, reported more often by women in peri- or postmenopause than before it5.

How well does hormone therapy work on hot flashes?

Better than anything else tested. A Cochrane review of 24 placebo-controlled trials with 3,329 women found oral hormone therapy cut weekly hot flashes by 75% against placebo and made the ones left much milder6. Placebo itself cut them by 57.7% from the start of the trials, which is why any hot-flash remedy needs a blinded trial before its claims mean anything6. The Menopause Society's 2022 position statement calls hormone therapy the most effective treatment for hot flashes and for the genitourinary syndrome of menopause (vaginal dryness, pain with sex and urinary symptoms), and says it prevents bone loss and fracture7.

Women with a uterus take a progestogen alongside estrogen, because estrogen alone thickens the uterine lining and raises the risk of endometrial cancer; women who have had a hysterectomy can take estrogen alone14. When dryness and urinary symptoms are the only problem and over-the-counter products have not helped, the statement recommends low-dose vaginal estrogen or another local therapy7.

What did the Women's Health Initiative actually find?

The Women's Health Initiative (WHI) was two randomised trials in 27,347 women aged 50 to 79, with an average age of 63, more than a decade past the median age of menopause [10, 12]. Women with a uterus took conjugated estrogens plus medroxyprogesterone acetate or placebo; women without one took the estrogen alone or placebo [8, 9]. Events per 10,000 women per year (the same as per 1,000 women over 10 years):

OutcomeEstrogen plus progestin (5.2 years)Estrogen alone (6.8 years)
Coronary heart disease7 more8No clear change9
Stroke8 more812 more9
Blood clot in the lung8 more8No clear change9
Invasive breast cancer8 more8Fewer: 168 vs 216 cases over 13 years10
Hip fracture5 fewer86 fewer9
Colorectal cancer6 fewer8No clear change9

Over 18 years, death from any cause was the same: 27.1% of women on hormones and 27.6% on placebo12. The combined arm was stopped in 2002, when its breast cancer result crossed the trial's stopping boundary8.

Does starting age change the risk?

Yes. In a reanalysis of both WHI trials, women who started within 10 years of menopause had 6 fewer heart disease events per 10,000 per year, while women 20 or more years past it had 17 more, a trend just short of the authors' significance bar11. Across all the serious outcomes tracked, estrogen alone in women aged 50 to 59 came to 19 fewer harmful events per 10,000 per year, and 51 more at 70 to 79; with the progestin it was 12 more and 38 more10. Stroke was the exception: its risk was raised whatever the age or time since menopause11.

The Menopause Society's position follows the same line: for women under 60 or within 10 years of menopause with no reason to avoid it, the balance is favourable for bothersome hot flashes and to prevent bone loss; started later, the absolute risks of heart disease, stroke, blood clots and dementia are greater7. Type, dose, route and duration change the risk too7. Whether to start, and which product, is a decision for you and your prescriber.

What does the hormone therapy label say now?

The FDA began removing the boxed warning statements on heart disease, breast cancer and probable dementia from menopausal hormone therapy labels in November 2025, and approved the first six revised labels on February 12, 202613. The estradiol patch Minivelle's label (DailyMed, November 16, 2026) shows the result: its boxed warning now covers one risk, endometrial cancer from estrogen without a progestogen in a woman with a uterus, and its dosing section asks prescribers to consider starting in women under 60 or within 10 years of menopause14. The label still lists who should not take it, including women with a history of breast cancer or blood clots14.

When to get help Bleeding after your periods have stopped for a year, on hormone therapy or not, is a reason to see your clinician soon, so the lining of the uterus can be checked14.

What are the non-hormonal prescription options?

Two once-daily pills block the neurokinin signals behind hot flashes on nerve cells in the brain's temperature-control centre: fezolinetant (Veozah, approved 2023) blocks the NK3 receptor, and elinzanetant (Lynkuet, approved 2025) blocks NK1 and NK3 [15, 17]. Both were tested in women with about 7 or more moderate to severe hot flashes a day (at least 50 a week for elinzanetant) [15, 17].

Week 12, per dayFezolinetant 45 mg (SKYLIGHT 1)Elinzanetant 120 mg (OASIS 1)Elinzanetant 120 mg (OASIS 2)
Hot flashes at the start10.41513.41714.717
Drop on the drug6.4158.7179.717
Drop on placebo3.9155.4176.517
Extra drop over placebo2.6153.2173.217

Fezolinetant's effect showed in the first week and held to 52 weeks16. Elinzanetant, taken at bedtime, also improved sleep disturbance and menopause quality of life at week 1218. Elinzanetant shows the larger extra drop, but the trials were separate, so this is not a head-to-head result. Fezolinetant carries a boxed warning for liver injury, with liver blood tests before starting and at months 1, 2, 3, 6 and 915. Elinzanetant's label asks for liver tests before starting and at 3 months, and warns about daytime sleepiness17. Its most common side effects were headache, fatigue, dizziness and sleepiness17.

Why does your body change shape in the transition?

Because fat and muscle change course while the scale barely does. In SWAN's body scans, the rate of fat gain nearly doubled from about 2 years before the final period, from about 0.25 kg a year to 0.45 kg, and lean mass, which had been rising, began to fall19. Both trends ran until about 2 years after the final period, then flattened19. Over that roughly 3.5-year stretch it came to about 1.6 kg more fat and 0.2 kg less lean mass, while weight kept rising at the same slow rate as before19. The scale hides the shift; body fat shows it.

Where do GLP-1s fit?

GLP-1 drugs treat weight, not hot flashes, and menopause did not blunt them: in SURMOUNT-1, women on tirzepatide lost 26%, 23% and 23% of body weight before, during and after menopause, against 2 to 3% on placebo20. Our guide GLP-1s and menopause covers those trials and hormone therapy taken alongside them.

Track it in the app

Sources

  1. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):387-395. PubMed 22343510
  2. El Khoudary SR, Greendale G, Crawford SL, et al. The menopause transition and women's health at midlife: a progress report from the Study of Women's Health Across the Nation (SWAN). Menopause. 2019;26(10):1213-1227. PubMed 31568098
  3. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531-539. PubMed 25686030
  4. Kravitz HM, Zhao X, Bromberger JT, et al. Sleep disturbance during the menopausal transition in a multi-ethnic community sample of women. Sleep. 2008;31(7):979-990. PubMed 18652093
  5. Gold EB, Sternfeld B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol. 2000;152(5):463-473. PubMed 10981461
  6. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;(4):CD002978. PubMed 15495039
  7. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. PubMed 35797481
  8. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. PubMed 12117397
  9. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712. PubMed 15082697
  10. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368. PubMed 24084921
  11. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-1477. PubMed 17405972
  12. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. 2017;318(10):927-938. PubMed 28898378
  13. U.S. Food and Drug Administration. FDA approves labeling changes to menopausal hormone therapy products. News release, February 12, 2026. fda.gov
  14. Noven Therapeutics. MINIVELLE (estradiol transdermal system), prescribing information (DailyMed, SPL version 22, published November 16, 2026): boxed warning, sections 2.1, 4 and 5.2. dailymed.nlm.nih.gov
  15. Astellas Pharma. VEOZAH (fezolinetant) tablets, prescribing information (DailyMed, SPL version 8, published March 6, 2026): boxed warning, sections 2.1, 6.1 and 14.1 (Table 2). dailymed.nlm.nih.gov
  16. Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091-1102. PubMed 36924778
  17. Bayer HealthCare Pharmaceuticals. LYNKUET (elinzanetant) capsules, prescribing information (DailyMed, SPL version 10, published August 4, 2026): sections 2, 5.1, 5.2, 6.1 and 14.1 (Table 4). dailymed.nlm.nih.gov
  18. Pinkerton JV, Simon JA, Joffe H, et al. Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials. JAMA. 2024;332(16):1343-1354. PubMed 39172446
  19. Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865. PubMed 30843880
  20. Tchang BG, Mihai AC, Stefanski A, et al. Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity (Silver Spring). 2025;33(5):851-860. PubMed 40074721

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo